Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one
2. Da 1229
3. Da-1229
4. Da1229
1. Da-1229
2. Evogliptin [inn]
3. 1222102-29-5
4. Chembl1779710
5. Evogliptin (inn)
6. Da1229
7. (r)-4-((r)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl)-3-(t-butoxymethyl)-piperazin-2-one
8. (r)-4-((r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one
9. 2-piperazinone, 4-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-3-((1,1-dimethylethoxy)methyl)-, (3r)-
10. 09118300l7
11. (r)-4-((r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazine-2-one
12. Unii-09118300l7
13. Evogliptin [who-dd]
14. Schembl343846
15. Dtxsid00153545
16. Bdbm50344779
17. Db12625
18. Hy-117985
19. Cs-0068793
20. C92448
21. D11023
22. Q25103700
23. (r)-4-[(r)-3-amino-4-(2,4,5-trifluorophenyl) Butanoyl]-3-(t-butoxymethyl)piperazin-2-one
24. (r)-4-[(r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(t-butoxymethy)piperazin-2-one
25. (3r)-4-[(3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(tert-butoxymethyl)piperazin-2-one
26. (3r)-4-[(3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one
27. (r)-4-[(r)-3-amino-4-(2,4,5-trifluorophenyl) Butanoyl]-3-(t-butoxymethyl)piperazine-2-one
28. 8vu
Molecular Weight | 401.4 g/mol |
---|---|
Molecular Formula | C19H26F3N3O3 |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 401.19262619 g/mol |
Monoisotopic Mass | 401.19262619 g/mol |
Topological Polar Surface Area | 84.7 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 558 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
A10BH07 - Evogliptin
Registrant Name : Estifarm Co., Ltd.
Registration Date : 2015-10-07
Registration Number : 1301-4-ND
Manufacturer Name : Estifarm Co., Ltd.
Manufacturer Address : 231, Hyeop-ro, Siheung-si, Gyeonggi-do
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
43
PharmaCompass offers a list of Evogliptin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Evogliptin manufacturer or Evogliptin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Evogliptin manufacturer or Evogliptin supplier.
PharmaCompass also assists you with knowing the Evogliptin API Price utilized in the formulation of products. Evogliptin API Price is not always fixed or binding as the Evogliptin Price is obtained through a variety of data sources. The Evogliptin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Evogliptin Tatrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Evogliptin Tatrate, including repackagers and relabelers. The FDA regulates Evogliptin Tatrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Evogliptin Tatrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Evogliptin Tatrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Evogliptin Tatrate supplier is an individual or a company that provides Evogliptin Tatrate active pharmaceutical ingredient (API) or Evogliptin Tatrate finished formulations upon request. The Evogliptin Tatrate suppliers may include Evogliptin Tatrate API manufacturers, exporters, distributors and traders.
click here to find a list of Evogliptin Tatrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Evogliptin Tatrate Drug Master File in Korea (Evogliptin Tatrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Evogliptin Tatrate. The MFDS reviews the Evogliptin Tatrate KDMF as part of the drug registration process and uses the information provided in the Evogliptin Tatrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Evogliptin Tatrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Evogliptin Tatrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Evogliptin Tatrate suppliers with KDMF on PharmaCompass.
Evogliptin Tatrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Evogliptin Tatrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Evogliptin Tatrate GMP manufacturer or Evogliptin Tatrate GMP API supplier for your needs.
A Evogliptin Tatrate CoA (Certificate of Analysis) is a formal document that attests to Evogliptin Tatrate's compliance with Evogliptin Tatrate specifications and serves as a tool for batch-level quality control.
Evogliptin Tatrate CoA mostly includes findings from lab analyses of a specific batch. For each Evogliptin Tatrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Evogliptin Tatrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Evogliptin Tatrate EP), Evogliptin Tatrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Evogliptin Tatrate USP).